ADAP01

**ADAP01** is an undisclosed preclinical **CAR-T cell therapy** being developed by **Adaptimmune** in collaboration with **Noile-Immune** as part of a co-pipeline program. Based on the available pipeline information, the product is a target-specific engineered T-cell therapy intended to direct cytotoxic T-cell activity against tumor cells expressing an undisclosed antigen, but the precise target, cancer indication, construct design, and clinical setting have not been publicly disclosed. The program appears to remain in **preclinical development**.

Other names

ADAP01-Adaptimmune-undisclosed-CAR-T cell therapyADAP-01-Adaptimmune-undisclosed-CAR-T cell therapyADAP 01-Adaptimmune-undisclosed-CAR-T cell therapy